Bigot et al constructed the GRIm score based on LDH, NLR, and ALB was first proposed to better select patients in clinical trials of immunotherapy, and results showed that the GRIm score was a better prognostic index for patients included in the experimental trials.[15,18] In recent years, the prognostic values of GRIm scores in non-small cell lung cancer,[35] small cell lung cancer[36] and esophageal squamous cell carcinoma[18] were improved. This evidence concerns the gene ALB and non-small cell lung carcinoma.